Asian Healthcare Equity Fundraising Reaches Record Levels
Equity capital fundraising for Asian healthcare firms reached record levels of $8.7 billion year-to-date – a 165 percent surge.
The healthcare sector accounted for the majority of equity capital market activity in Asia Pacific, representing 14.7 percent of total proceeds year-to-date, according to Refinitiv data.
China dominated APAC healthcare equity markets, accounting for 72 percent ($6.3 billion) of total proceeds in the period. The sector’s activities were made up primarily of smaller-sized deals headlined by China’s Sino Biopharmaceutical which issued $828.9 million in convertible bonds. Wuxi Biologics was the other notable Chinese healthcare player, raising over $1.35 billion.
Global Healthcare
Globally, healthcare equity capital markets raised $23.6 billion including $4.6 billion from IPO proceeds, a 46 percent spike. Biotechnology and pharmaceuticals represented the majority of listings with a 57 percent market share.
Regionally, the U.S. was the leader in healthcare ECM proceeds with 44.5 percent market share. China and Europe held a 26.6 percent and 13.2 percent market share during the period, respectively.
